Figure 3.
Kaplan‐Meier curve of progression‐free survival in the intent‐to‐treat population. (A): Progression‐free survival was 4.14 months (95% CI, 3.38–4.50) in the anlotinib group and 1.45 months (1.41–1.51) in the placebo group, with a hazard ratio of 0.34 (95% CI, 0.27–0.43, p < 0.0001). (B): subgroup analysis for progression‐free survival. Abbreviations: CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; VEGF, vascular endothelial growth factor.